

under method 1 are based on data collected by the Basel Committee on Banking Supervision (BCBS). The BCBS amounts are determined based on the sum of the systemic indicator amounts as reported by the 75 largest U.S. and foreign banking organizations as measured by the BCBS, and any other banking organization that the BCBS includes in its sample total for that year. The BCBS publicly releases these

amounts, denominated in euros, each year.<sup>3</sup> Pursuant to the GSIB surcharge rule, the Board publishes the aggregate global indicator amounts each year as denominated in U.S. dollars using the euro-dollar exchange rate provided by the BCBS.<sup>4</sup> Specifically, to determine the 2024 aggregate global indicator amounts, the Board uses the year-end 2023 euro-denominated indicator amounts published by the BCBS and

multiplies each of the euro-denominated indicator amounts by 1.105, the euro to U.S. dollar spot exchange rate on December 31, 2023.<sup>5</sup>

The aggregate global indicator amounts expressed in U.S. dollars for purposes of the 2024 method 1 score calculation under § 217.404(b)(1)(i)(B) of the GSIB surcharge rule are:

AGGREGATE GLOBAL INDICATOR AMOUNTS IN U.S. DOLLARS (USD) FOR 2024

Category	Systemic indicator	Aggregate global indicator amount (in USD)
Size	Total exposures	\$115,205,051,188,518
Interconnectedness	Intra-financial system assets	11,253,226,663,114
	Intra-financial system liabilities	11,388,383,441,235
Substitutability	Securities outstanding	19,247,590,871,111
	Payments activity	3,527,103,136,881,927
	Assets under custody	219,479,268,261,988
Complexity	Underwritten transactions in debt and equity markets	7,962,804,019,185
	Notional amount of over-the-counter (OTC) derivatives	733,514,990,056,729
	Trading and available-for-sale (AFS) securities	4,278,831,961,372
Cross-jurisdictional activity	Level 3 assets	803,127,442,989
	Cross-jurisdictional claims	28,416,427,492,687
	Cross-jurisdictional liabilities	23,524,643,383,930

*Authority:* 12 U.S.C. 248(a), 321–338a, 481–486, 1462a, 1467a, 1818, 1828, 1831n, 1831o, 1831p–l, 1831w, 1835, 1844(b), 1851, 3904, 3906–3909, 4808, 5365, 5368, 5371.

By order of the Board of Governors of the Federal Reserve System, acting through the Director of Supervision and Regulation under delegated authority.

**Ann E. Misback,**  
Secretary of the Board.

[FR Doc. 2024–29981 Filed 12–17–24; 8:45 am]

BILLING CODE 6210–01–P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Agency for Healthcare Research and Quality**

**Notice of Meetings**

**AGENCY:** Agency for Healthcare Research and Quality (AHRQ), Department of Health and Human Services (HHS).

**ACTION:** Notice of five AHRQ subcommittee meetings.

**SUMMARY:** The subcommittees listed below are part of AHRQ’s Health Services Research Initial Review Group (IRG) Committee. Grant applications are

to be reviewed and discussed at these meetings. Each subcommittee meeting will be closed to the public.

**DATES:** See below for dates of meetings:

1. *Healthcare Safety and Quality Improvement Research (HSQR).*

*Date:* February 5–6, 2025.

2. *Healthcare Effectiveness and Outcomes Research (HEOR).*

*Date:* February 5–6, 2025.

3. *Health System and Value Research (HSVR).*

*Date:* February 13–14, 2025.

4. *Healthcare Research Training (HCRT).*

*Date:* February 27–28, 2025.

5. *Healthcare Information Technology Research (HITR).*

*Date:* February 27–28, 2025.

**ADDRESSES:** Agency for Healthcare Research and Quality (Virtual Review), 5600 Fishers Lane, Rockville, Maryland 20857.

**FOR FURTHER INFORMATION CONTACT:** (to obtain a roster of members, agenda or minutes of the non-confidential portions of the meetings.)Jenny Griffith, Committee Management Officer, Division of Policy, Coordination and Analysis, Office of Extramural Research Education and Priority Populations, Agency for Healthcare Research and Quality (AHRQ), 5600 Fishers Lane,

Rockville, Maryland 20857, telephone (301) 427–1557.

**SUPPLEMENTARY INFORMATION:** In accordance with the Federal Advisory Committee Act, 5 U.S.C. 1009(a)(2), AHRQ announces meetings of the above-listed scientific peer review groups, which are subcommittees of AHRQ’s Health Services Research Initial Review Group Committee. The subcommittee meetings will be closed to the public in accordance with the provisions set forth in 5 U.S.C. 1009(d), 5 U.S.C. 552b(c)(4), and 5 U.S.C. 552b(c)(6). The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Agenda items for these meetings are subject to change as priorities dictate.

Dated: December 12, 2024.

**Marquita Cullom,**  
Associate Director.

[FR Doc. 2024–29969 Filed 12–17–24; 8:45 am]

BILLING CODE 4160–90–P

<sup>3</sup> The data used by the Board are available on the BCBS website at <https://www.bis.org/bcb/gsib/denominators.htm>.

<sup>4</sup> 12 CFR 217.404(b)(1)(i)(B); see also 80 FR 49082, 49086–87 (August 14, 2015). In addition, the Board

maintains the GSIB Framework Denominators on its website, available at <https://www.federalreserve.gov/supervisionreg/basel/denominators.htm>.

<sup>5</sup> Foreign exchange rates provided by the BCBS. Available at [https://www.bis.org/bcb/gsib/reporting\\_instructions.htm](https://www.bis.org/bcb/gsib/reporting_instructions.htm).